GENinCode UK Ltd. AI Stock Analysis
Want to see GB:GENI full AI Analyst Report?
GENinCode UK Ltd. (GENI) AI Stock Analysis
GENinCode UK Ltd.
(LSE:GENI)
The score is primarily constrained by severe losses, sustained cash burn, and a fragile balance sheet. Weak technical trends and the negative P/E provide little additional support, resulting in a very low overall stock score.
GENinCode UK Ltd. (GENI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 4.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.70M
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- -0.43
- Revenue Growth
- -10.81%
- EPS Growth
- 42.67%
- Country
- UK
- Employees
- 44
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
GENinCode UK Ltd. Business Overview & Revenue Model
Company Description
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology...
GENinCode UK Ltd. Financial Statement Overview
Summary
Revenue growth and potentially attractive gross margins are outweighed by substantial operating and net losses, persistent negative operating and free cash flow, a sharply reduced equity base, and debt exceeding equity.
Income Statement
32NegativeBalance Sheet
27NegativeCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.60M | 3.08M | 2.70M | 2.16M | 1.43M | 1.15M |
| Gross Profit | 1.32M | 1.54M | 1.43M | 1.02M | 632.00K | 593.00K |
| EBITDA | -5.77M | -5.63M | -4.69M | -6.65M | -5.57M | -4.10M |
| Net Income | -5.26M | -5.71M | -4.43M | -7.02M | -5.56M | -4.14M |
Balance Sheet | ||||||
| Total Assets | 3.53M | 2.38M | 2.66M | 4.19M | 11.80M | 15.21M |
| Cash, Cash Equivalents and Short-Term Investments | 2.05M | 895.00K | 1.17M | 2.53M | 9.75M | 14.56M |
| Total Debt | 98.00K | 146.00K | 234.00K | 299.00K | 354.00K | 0 |
| Total Liabilities | 1.47M | 2.25M | 1.54M | 2.90M | 3.90M | 1.49M |
| Stockholders Equity | 2.06M | 124.00K | 1.13M | 1.29M | 7.90M | 13.72M |
Cash Flow | ||||||
| Free Cash Flow | -3.96M | -4.11M | -5.22M | -7.54M | -4.61M | -3.17M |
| Operating Cash Flow | -3.91M | -4.07M | -5.17M | -7.51M | -3.76M | -3.02M |
| Investing Cash Flow | -48.00K | -44.00K | 50.00K | 136.00K | -849.00K | -145.00K |
| Financing Cash Flow | 4.21M | 3.64M | 3.65M | -94.00K | -47.00K | 15.86M |
GENinCode UK Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Negative. The current price of 0.60 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.72, and below the 200-day MA of 0.95, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 41.05 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENI.
GENinCode UK Ltd. Peers Comparison
Overall Rating
GB:GDR49Neutral
GB:CLBX48Neutral
GB:ABDX46Neutral
GB:RENX44Neutral
GB:OBD40Underperform- GB:GENI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 14.45M | -0.82 | -1044.57% | ― | 65.60% | 74.84% |
| GB:CLBX | 48Neutral | GBP 6.82M | -0.49 | -104.73% | ― | -56.10% | 41.10% |
| GB:ABDX | 46Neutral | GBP 21.48M | -15.45 | -34.31% | ― | 30.42% | 43.16% |
| GB:RENX | 44Neutral | GBP 36.20M | -3.37 | 675.00% | ― | ― | ― |
| GB:OBD | 40Underperform | GBP 16.13M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
| GB:GENI | 40Underperform | GBP 4.37M | -0.45 | -481.34% | ― | -10.81% | 42.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:GENI | GENinCode UK Ltd. | 0.60 | -1.70 | -73.91% | |
| GB:CLBX | ANGLE plc | 0.60 | -1.20 | -66.67% | |
| GB:GDR | Genedrive plc | 0.90 | 0.11 | 13.92% | |
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:RENX | Renalytix Plc OTC | 5.40 | -1.85 | -25.52% | |
| GB:ABDX | Abingdon Health PLC | 8.50 | 1.00 | 13.33% |
GENinCode UK Ltd. Corporate Events
GENinCode narrows losses as it advances global rollout of genetic heart and ovarian cancer tests
NeutralGENinCode reported interim revenue of £1.1m for the six months to 30 June 2026, down from £1.6m a year earlier, as NHS cutbacks and the absence of prior-year Catalonia pilot income weighed on sales. Adjusted EBITDA losses narrowed to £2.26m, supporte...
GENinCode sets date for interim results as genetic risk platform gains strategic momentum
PositiveGENinCode Plc will publish its unaudited interim results for the six months ended 30 June 2026 on 29 September 2026, and has scheduled a briefing for equity research analysts that morning in Oxford. The update underscores the company’s progress in pr...
GENinCode to unveil interim results as genetic risk tools gain clinical traction
PositiveGENinCode will publish its unaudited interim results for the six months to 30 June 2026 on 29 September 2026 and is hosting an analyst briefing the same day in Oxford, underscoring its engagement with the investment community. The announcement highli...
GENinCode Pilot Backs Genetic Scoring for Coronary Risk in Primary Care
PositiveGENinCode reported preliminary real-world data from a Catalan primary care pilot showing its CARDIO inCode-Score polygenic risk test significantly refines coronary artery disease risk classification in moderate-risk patients. The study of 584 adults...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026